- Record: found
- Abstract: found
- Article: not found
Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.
Ling Zhang
1 ,
Richard A Morgan
1 ,
Joal D Beane
1 ,
Zhili Zheng
1 ,
Mark E Dudley
1 ,
Sadik H Kassim
1 ,
Azam V Nahvi
1 ,
Lien T Ngo
1 ,
Richard M Sherry
1 ,
Giao Q Phan
1 ,
Marybeth S Hughes
1 ,
Udai S Kammula
1 ,
Steven A Feldman
1 ,
Mary Ann Toomey
1 ,
Sid P Kerkar
1 ,
Nicholas P Restifo
1 ,
James C Yang
1 ,
Steven A Rosenberg
2
May 15 2015
Read this article at
ScienceOpenPublisherPubMed
- oa repository (via OAI-PMH doi match)
- oa repository (via pmcid lookup)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
Powered by 
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Infusion of interleukin-12 (IL12) can mediate antitumor immunity in animal models, yet its systemic administration to patients with cancer results in minimal efficacy and severe toxicity. Here, we evaluated the antitumor activity of adoptively transferred human tumor-infiltrating lymphocytes (TILs) genetically engineered to secrete single-chain IL12 selectively at the tumor site.